Product Data Sheet

R121919

Cat. No.:HY-14127CAS No.:195055-03-9Molecular Formula: $C_{22}H_{32}N_6$ Molecular Weight:380.53Target:CRFR

Pathway: GPCR/G Protein

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

Ethanol: 100 mg/mL (262.79 mM; Need ultrasonic) DMSO: 6.2 mg/mL (16.29 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.6279 mL	13.1396 mL	26.2791 mL
	5 mM	0.5256 mL	2.6279 mL	5.2558 mL
	10 mM	0.2628 mL	1.3140 mL	2.6279 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.5 mg/mL (6.57 mM); Clear solution
- 2. Add each solvent one by one: 10% EtOH >> 90% (20% SBE- β -CD in saline) Solubility: 2.5 mg/mL (6.57 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% EtOH >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.57 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 1.79 mg/mL (4.70 mM); Clear solution
- 5. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: 1.79 mg/mL (4.70 mM); Suspended solution; Need ultrasonic
- 6. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.79 mg/mL (4.70 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	R121919 (NBI30775) is a potent and selective CRF1R antagonist with a K_i of 2 to 5 nM. R121919 has antidepressant and anxiolytic effects. R121919 alleviates defensive withdrawal in rats ^{[1][2][3]} .	
IC ₅₀ & Target	CRFR1 2-5 nM (Ki)	
In Vitro	R121919 is a potent small-molecule CRF1 receptor antagonistwith high affinity for the CRF1 receptor and over 1000-fold weaker activity at the CRF2 receptor, CRF-binding protein, or 70 other receptor types ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	R121919 (NBI30775) dose dependently decreases adrenocorticopin hormone and Corticosterone (HY-B1618) responses to restraint stress in rats. Peak plasma adrenocorticopin hormone and corticosterone concentrations at a dose of 10 mg/kg R121919 are 9 and 25%, respectively ^[1] . R121919 reduces levels of anxiety in mice with a steep dose-response curve ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

PROTOCOL

Animal Administration [1][2]

Rats: For the restraint stress,R121919 is dissolved in an aqueous 70% (v/v) polyethylene glycol 400 solution, and serially diluted in this vehicle to the appropriate concentrations. The drug is injected i.v. in a volume of 1 mL/kg to Male Sprague-Dawley rats. For the defensive withdrawal experiments, R121919 solutions are made fresh the night before each experiment. R121919 is dissolved in a vehicle consisting of 5% (v/v) polyethoxylated castor oil^[1].

Mice: R121919 is dissolved in an aqueous. The drug is administered orally (1 mL/100 g bodyweight) via a feeding tube to six to ten mice per group; the doses applied are 0.5, 1.0 and 5.0 mg/kg for the DBA/2NCRL mice and 1.0, 5.0, and 30 mg/kg for the DBA/2Ola strain; an additional (vehicle) group of mice receives water, while a further group of mice (untreated controls) are spared the aforementioned manipulations^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

SSRN, 2023 Jul 18.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Gutman DA, et al. Behavioral effects of the CRF1 recepator antagonist R121919 in rats selectively bred for high and low activity in the swim test. Psychoneuroendocrinology. 2008 Sep;33(8):1093-101.

[2]. Gutman DA, et al. The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther. 2003 Feb;304(2):874-80.

[3]. Post A, et al. Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). Psychopharmacology (Berl). 2005 Jun;180(1):150-8.

Page 2 of 3 www.MedChemExpress.com

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 3 of 3 www.MedChemExpress.com